Related Experiment Video
Updated: Oct 12, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Screening Novel Drug Candidates for Kidney Renal Clear Cell Carcinoma Treatment: A Study on Differentially Expressed
Bin Gao1, Lijuan Wang1, Na Zhang1
1Department of Urology, Tangshan Central Hospital, Tangshan, China.
Objective:
Kidney renal clear cell carcinoma (KIRC) is a common cancer with high morbidity and mortality in renal cancer. Thus, the transcriptome data of KIRC patients in The Cancer Genome Atlas (TCGA) database were analyzed and drug candidates for the treatment of KIRC were explored through the connectivity map (CMap) database.
Methods:
The transcriptome data of KIRC patients were downloaded from TCGA database, and KIRC-associated hub genes were screened out through differential analysis and protein-protein interaction (PPI) network analysis. Afterward, the CMap database was used to select drug candidates for KIRC treatment, and the drug-targeted genes were obtained through the STITCH database. A PPI network was constructed by combining drug-targeted genes with hub genes that affected the pathogenesis of KIRC to obtain final hub genes. Finally, combining hub genes and KIRC-associated hub genes, the pathways affected by drugs were explored by pathway enrichment analysis.
Results:
A total of 2,312 differentially expressed genes were found in patients, which were concentrated in immune cell activity, cytokine, and chemokine secretion pathways. Drug screening disclosed 5 drug candidates for KIRC treatment: fedratinib, Ly344864, geldanamycin, AS-605240, and luminespib. Based on drug-targeted genes and KIRC-associated hub genes, 16 hub genes were screened out. Pathway enrichment analysis revealed that drugs mainly affected pathways such as neuroactive ligand pathways, cell adhesion, and chemokines.
Conclusion:
The above results indicated that fedratinib, LY 344864, geldanamycin, AS-605240, and luminespib could be used as candidates for KIRC therapy. The findings from this study will make contributions to the treatment of KIRC in the future.
Insights
This study identified five potential drug candidates, including fedratinib and geldanamycin, for treating kidney renal clear cell carcinoma (KIRC) by analyzing patient transcriptome data and drug targets.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Kidney renal clear cell carcinoma (KIRC) presents significant morbidity and mortality.
- Effective therapeutic strategies for KIRC are urgently needed.
Purpose of the Study:
- To analyze KIRC transcriptome data from The Cancer Genome Atlas (TCGA).
- To identify potential drug candidates for KIRC treatment using the Connectivity Map (CMap) database.
Main Methods:
- Downloaded and analyzed TCGA transcriptome data for KIRC.
- Screened KIRC-associated hub genes using differential expression and protein-protein interaction (PPI) network analysis.
- Utilized CMap and STITCH databases to identify drug candidates and their targets, constructing a final PPI network.
Main Results:
- Identified 2,312 differentially expressed genes in KIRC, primarily in immune cell activity and cytokine pathways.
- Disclosed five drug candidates: fedratinib, Ly344864, geldanamycin, AS-605240, and luminespib.
- Filtered 16 hub genes and found that the identified drugs affect neuroactive ligand, cell adhesion, and chemokine pathways.
Conclusions:
- Fedratinib, LY 344864, geldanamycin, AS-605240, and luminespib show promise as therapeutic candidates for KIRC.
- These findings contribute to the development of future KIRC treatments.
